Each year, the release of the U.S. Trade Representative’s Special 301 Report offers an important reminder: strong intellectual property protections do not stop at the United States border. For American innovators to compete, grow, and succeed globally, they need fair treatment in foreign markets and confidence that foreign nations will protect their inventions.
This year’s report underscores both progress and persistent challenges. Argentina’s move off the Priority Watch List signals that improvement is possible. But continued concerns in several other countries and regions temper that progress. China and India remain on the Priority Watch List, and Brazil, Mexico, and Canada face scrutiny on the Watch List. The addition of the European Union to the Watch List for the first time in 20 years underscores that even advanced economies are moving in directions that raise new concerns for innovators.
In several of these markets, the IP abuses are extensive. In China, policy that limits what qualifies as a “new drug,” weaknesses in its patent linkage system, and recent efforts to set global licensing rates for standard-essential patents all continue to disadvantage U.S. innovators. At the same time, persistent challenges with large-scale counterfeiting and piracy — affecting both physical goods and digital content — undermine legitimate markets and weaken incentives to invest in new products and creative enterprises.
India’s restrictive patentability standards, lengthy patent grant timelines, and the absence of an effective system for resolving pharmaceutical patent disputes create ongoing uncertainty for innovators, particularly for companies developing new medicines. Mexico, meanwhile, has yet to fully meet its commitments under USMCA and continues to “free ride” on U.S. pharmaceutical innovation. Concerns also remain regarding inadequate enforcement against counterfeit goods and copyright violations, which further distort fair competition.
Brazil’s continued inclusion on the Watch List reflects recent administrative backlogs that erode the effective life of patents and reduce their value, as well as long-standing concerns regarding illicit streaming and the distribution and sale of counterfeits. In Canada, policies including price-setting mechanisms and broader regulatory frameworks limit the return innovators can earn and, therefore, suppress the value of their IP. Like Mexico, Canada is also failing to uphold its USMCA IP obligations, particularly in seizing counterfeit goods and applying penalties for online piracy and counterfeit distribution, which pose significant risks to creative and retail industries.
The most striking addition to this year’s report is the placement of the European Union, which marks a notable shift from past reports and reflects growing concern about recent policy developments in the region. As a major innovation hub, the EU’s approach to intellectual property carries influence well beyond its borders.
In the EU, pharmaceutical reforms that shorten regulatory data protection and make it difficult to obtain injunctive relief raise serious questions about how strongly the EU will protect innovation in the future.
These designations are more than procedural. They indicate whether American innovators can operate globally with confidence that foreign nations will honor their IP and protect their ideas. Weak patent systems, unclear regulatory frameworks, and limited enforcement mechanisms can make it difficult for companies to bring new technologies to market — and even harder to defend them once they do. And weak enforcement against counterfeiting and copyright infringement undermines even well-established IP rights and endangers entire industries.
At a time when global competition is intensifying, ensuring strong and enforceable IP protections abroad remains essential to sustaining American innovation and economic leadership.
C4IP appreciates USTR’s continued leadership and its ongoing commitment to strengthening intellectual property protections around the world.